ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Vivus Submits Qnexa Response To FDA; Meeting Set For January

DOW JONES NEWSWIRES Vivus Inc. (VVUS) said it has responded to the U.S. Food and Drug Administration's concerns about obesity drug Qnexa and has set a meeting for late January to discuss the company's latest effort to win its approval. The disclosure follows an FDA panel's positive recommendation last week of Orexigen Therapeutics Inc.'s (OREX) weight-loss drug Contrave. The FDA doesn't have to follow the panel's recommendation, but the positive vote puts Orexigen ahead of Vivus and Arena Pharmaceuticals Inc. (ARNA)--which received negative recommendations from similar panels earlier this year--by easing investor concerns that major clinical studies would be needed before approval. The FDA in October issued a "complete response letter" for Qnexa saying it couldn't approve the drug application in its current form. The agency asked the company for a comprehensive assessment of Qnexa's potential to cause birth defects and for Vivus to provide evidence that the product doesn't increase the risk for major adverse cardiovascular events. The company said the FDA didn't request a new clinical trial, but asked for two-year study results involving Qnexa to be submitted. "Submission of our briefing document and confirmation of our meeting with the FDA indicate the continued progress Vivus is making in seeking U.S. approval of Qnexa for the treatment of obesity," Chief Executive Leland Wilson said Tuesday. "We are confident in the data analyses we have compiled in the briefing document, and we look forward to our meeting with the FDA." Vivus shares closed Monday at $9.42 and were inactive premarket. The stock is up 45% this month amid the positive news on Orexigen's Contrave. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Arena (ARNA)
02/11/201611:00:58Schedule 13g<br /> (sc 13g/a)
02/10/201614:46:54Amended Statement of Ownership (sc 13g/a)
01/25/201613:50:21Amended Statement of Ownership (sc 13g/a)
01/13/201609:41:00U.S. Hot Stocks: Hot Stocks to Watch
01/12/201616:55:03Current Report Filing (8-k)
01/12/201616:05:00Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to...
01/07/201608:00:00Arena Pharmaceuticals to Present at the 34th Annual J.P. Morgan...
12/04/201516:57:11Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade
12/04/201514:08:02Why Arena Pharmaceuticals, Inc. Bulked Up in November
12/03/201507:00:03Why Axovant Sciences Skyrocketed 56% in November
12/01/201517:05:24Current Report Filing (8-k)
12/01/201511:06:45Here's Why Arena Pharmaceuticals' Stock Briefly Spiked Today
12/01/201508:00:00Eisai and Arena Pharmaceuticals Announce Completion of Enrollment...
11/30/201519:40:38Why Ambarella, Arena Pharmaceuticals, and ITC Holdings Jumped...
11/30/201508:00:00Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New...
11/24/201508:00:00Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual...
11/19/201508:00:00Arena Pharmaceuticals to Host Analyst & Investor Day on December...
11/12/201511:00:033 Dangerous Stocks
11/10/201516:20:28Current Report Filing (8-k)
11/10/201516:00:00Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations